Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
APP-H51H6 | Human | Human APP / Abeta42 Protein, His Tag | ![]() |
||
APP-H51H7 | Human | Human APP / Abeta40 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
APP-H52H5 | Human | Human APP / SAPPbeta Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
APP-M52H3 | Mouse | Mouse APP / N-APP Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
The purity of Mouse N-APP, His Tag (Cat. No. APP-M52H3) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Florapronol (18F) | 18F-FC-119S; 18F-FC-119(S) | Approved | Korea Institute Of Radiological And Medical Sciences, Futurechem | Alzavue | Alzheimer Disease | Details | ||||
L-Lysine hydrochloride/Cyanocobalamin/Inositol | Approved | 兴邦 | Malnutrition | Details | ||||||
Immune Globulin Subcutaneous (Human) (Octapharma) | Approved | Octapharma | Cutaquig, Octanorm, Gammanorm | United States | Immunologic Deficiency Syndromes | null | 2018-08-02 | Immunologic Deficiency Syndromes | Details | |
Sodium Oligomannurarate | GV-971; 971 | Approved | Ocean University Of China, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 九期一 | Mainland China | Alzheimer Disease | Shanghai Greenvalley Pharmaceutical Co Ltd | 2019-11-02 | Alzheimer Disease; Parkinson Disease | Details |
Inositol | 4L6452S749 | Approved | Nicosit | Anovulation; Depression; Anxiety; Diabetic Neuropathies; Polycystic Ovary Syndrome; Glucose Intolerance; Insulin Resistance; Infant, Newborn, Diseases; Bronchopulmonary Dysplasia; Metabolic Diseases; Lung Neoplasms; Precancerous Conditions; Retinopathy of Prematurity; Infant, Premature, Diseases; Carcinoma, Non-Small-Cell Lung; Hyperandrogenism | Details | |||||
Immune globulin 10% (Grifols) | KIg-10; TAL-05-0002 | Approved | Bayer AG | Gamunex, Gammaked | United States | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Immunologic Deficiency Syndromes | null | 2003-08-27 | Postural Orthostatic Tachycardia Syndrome; Anemia, Sickle Cell; Corneal Neovascularization; Kidney Failure, Chronic; Immunologic Deficiency Syndromes; Muscular Diseases; Common Variable Immunodeficiency; Neuralgia; Reflex Sympathetic Dystrophy; Obsessive-Compulsive Disorder; Severe Combined Immunodeficiency; Primary Immunodeficiency Diseases; Anxiety Disorders; Autoimmune Diseases; Coronavirus Disease 2019 (COVID-19); Pain; Agammaglobulinemia; Tibial Fractures; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Wiskott-Aldrich Syndrome; Myasthenia Gravis | Details |
Flutemetamol (18F) | AH-110690; GE-067; 18F-GE067 | Approved | Ge Healthcare | Vizamyl | Japan | Contrast agents | Nihon Medi-Physics Co Ltd | 2013-10-25 | Atherosclerosis; Cardiomyopathies; Breast Neoplasms; Contrast agents; Cognitive Dysfunction; Alzheimer Disease; Dementia; Diagnostic agents; Hydrocephalus, Normal Pressure; Cognition Disorders | Details |
Florbetapir(18F) | MNI-798; AV-45 | Approved | Eli Lilly And Company | Amyvid | Japan | Diagnostic agents | Eli Lilly And Company | 2012-04-06 | Amyloidosis; Hypersensitivity; Frontotemporal Dementia; Neurodegenerative Diseases; Collagen Diseases; Eye Diseases; Diagnostic agents; Lewy Body Disease; Rheumatic Diseases; Respiration Disorders; Parkinson Disease; Cognitive Dysfunction; Alzheimer Disease; Contrast agents; Spasms, Infantile; Multiple Sclerosis; Skin Diseases | Details |
Aducanumab | BIIB-037; NI-10; BART | Approved | Eisai Co Ltd, Neurimmune Ag | ADUHELM | United States | Alzheimer Disease | Biogen Inc | 2021-06-07 | Alzheimer Disease; Cognitive Dysfunction | Details |
Florbetaben (18F) | MNI-815; AV-1; ZK-6013443; BAY-949172 | Approved | Piramal | Neuraceq | United States | Hyponatremia | Molecular Life Inc | 2014-02-20 | Supranuclear Palsy, Progressive; Down Syndrome; Hyponatremia; Immunoglobulin Light-chain Amyloidosis; Dementia; Alzheimer Disease; Amyloidosis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
[18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
RIV-1061-IR | RIV-1061; RIV-1061-IR | Phase 1 Clinical | Revivo Therapeutics | Alzheimer Disease; Cognition Disorders | Details |
11C-BF-227 | 11C-BF-227; [11C]BF-227 | Phase 2 Clinical | Tohoku University | Diagnostic agents | Details |
Abeta42 antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
[18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
RQ-9 | AAT-009; RQ-9; RQ-00000009 | Phase 1 Clinical | Pfizer Inc | Dementia | Details |
A ß antibody Fab | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
PRX-012 | PRX-012 | Phase 1 Clinical | Prothena | Alzheimer Disease | Details |
ASN-120290 | ASN-120290; ASN-561; ASN-90 | Phase 1 Clinical | Merck Serono | Alzheimer Disease | Details |
APH-1105 | APH-1105 | Aphios | Details | ||
Trontinemab | RO-7126209; RG-6102 | F. Hoffmann-La Roche Ltd | Details | ||
E-2212 | GSM-2; GSM-A; E-2212 | Eisai Co Ltd | Details | ||
AD-35 | AD-35 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Alzheimer Disease | Details |
Lu-AF-20513 | Lu-AF-20513 | H. Lundbeck A/S, Otsuka Pharmaceutical Co Ltd | Details | ||
Indole-3-propionic acid | SHP-22; SHP-622; VP-20629; OX-1; IN-OX1 | Intellect Neurosciences | Details | ||
SHR-1707 | SHR-1707 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Alzheimer Disease | Details |
UBITh AD immunotherapeutic vaccine (United Biomedical) | UB-311 | United Biomedical Inc | Details | ||
KHK-6640 | KHK-6640 | Immunas | Details | ||
PPI-1019 | PPI-1019 | Glaxosmithkline Plc | Details | ||
ALZ-101 | ALZ-101 | Phase 1 Clinical | Alzinova AB | Alzheimer Disease | Details |
AAB-003 | AAB-003; PF-5236812; PF-05236812 | Pfizer Pharmaceuticals Ltd (China), Elan Corp | Details | ||
Anatabine citrate | RCP-006 | Clinical | Rock Creek, Roskamp Institute | Alzheimer Disease; Inflammation | Details |
CAD-106 | CAD-106 | Kuros Biosciences, Novartis Pharma Ag | Details | ||
SAR-228810 | SAR-228810 | Sanofi | Details | ||
Aftobetin | ANCA-11 | Cognoptix Inc, University Of California San Diego | Details | ||
MRZ-99030 | EG-030; GAL-101; MRZ-99030 | Tel Aviv University Trust | Details | ||
Crenezumab | R-7412; RG-7412; RO-5490245; MABT-5102-A | Phase 2 Clinical | Ac Immune Sa, Genentech Inc | Alzheimer Disease | Details |
L-clausenamide | Phase 2 Clinical | Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Fuan Pharmaceutical (Group) Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd | Cognitive Dysfunction; Dementia; Memory Disorders | Details | |
18F-92 | 18F-92 | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Alzheimer Disease | Details |
Edonerpic | T-817 MA | Phase 2 Clinical | Toyama Chemical Co Ltd, Fujifilm Group | Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency | Details |
Inositol/Vitamin B1/Vitamin B2 | Details | ||||
Procaine Hydrochloride/Vitamin B6/Inositol | Details | ||||
Birtamimab | NEOD-001 | Phase 3 Clinical | Prothena | Immunoglobulin Light-chain Amyloidosis; Amyloidosis | Details |
123I-ABC-577 | 123I-ABC-577 | Clinical | Nihon Medi-Physics Co Ltd | Diagnostic agents | Details |
Valiltramiprosate | NRM-8499; ALZ-801; BLU-8499 | Phase 3 Clinical | Alzheon Inc | Alzheimer Disease | Details |
Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Down Syndrome; Chronic Traumatic Encephalopathy; Alzheimer Disease; Cognitive Dysfunction; Parkinson Disease; Frontotemporal Dementia | Details |
BEY-2153 | BEY-2153 | Phase 1 Clinical | Beyondbio Inc | Alzheimer Disease | Details |
Tarenflurbil spraygel (MIKA Pharma) | Clinical | Galen Ltd, Mika Pharma Gmbh | Pain; Arthritis, Rheumatoid; Skin Diseases; Inflammation; Dermatitis, Atopic | Details | |
ABvac-40 | ABvac-40 | Phase 2 Clinical | Araclon Biotech Sl | Alzheimer Disease; Cognitive Dysfunction | Details |
PRI-002 | RD-2; PRI-002 | Phase 1 Clinical | Priavoid | Cognitive Dysfunction; Alzheimer Disease | Details |
ALN-APP | Phase 1 Clinical | Sirna Therapeutics Inc | Cerebral Amyloid Angiopathy; Spinocerebellar Degenerations; Alzheimer Disease; Neurodegenerative Diseases | Details | |
Solanezumab | LY-2062430 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Dementia; Cognition Disorders | Details |
LY-3372993 | LY-3372993 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
ACU-193 | ACU-193; ACU193 | Phase 1 Clinical | Acumen Pharmaceuticals Inc | Alzheimer Disease | Details |
Gantenerumab | MAb-31; R-1450; RG-1450; R-04909832 | Phase 3 Clinical | Chugai Pharmaceutical Co Ltd | Dementia; Alzheimer Disease | Details |
AMDX-2011P | AMDX-2011P; AMDX2011P | Phase 1 Clinical | Amydis Inc | Parkinson Disease; Amyotrophic Lateral Sclerosis | Details |
CT-1812 | CT-1812; SV-119 | Phase 2 Clinical | Cogrx | Alzheimer Disease; Cognitive Dysfunction; Lewy Body Disease | Details |
Pittsburgh Compound B | [11C]PIB; [11C]6-OH-BTA-1; 11C-PIB | Phase 2 Clinical | The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet | Ovarian Neoplasms; Brain Concussion; Breast Neoplasms; Parkinson Disease; Alzheimer Disease; Alcoholism; Dementia | Details |
This web search service is supported by Google Inc.